Does furosemide improve renal function in patients stopping renal replacement therapy?

Submission date	Recruitment status	Prospectively registered
30/09/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	Individual participant data
02/02/2017	Urological and Genital Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Neil Soni

Contact details

Magill Dept of Anaesthetics, 3rd Floor, D Lift Chelsea & Westminster Hospital 369 Fulham Road London United Kingdom SW10 9NH +44 (0)20 8237 2763 n.soni@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0060110642

Study information

Scientific Title

Does furosemide improve renal function in patients stopping renal replacement therapy?

Study objectives

Does furosemide improve renal function in patients stopping renal replacement therapy?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial parallel design

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Urological and Genital Diseases: Renal function

Interventions

Furosemide vs no furosemide

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Furosemide

Primary outcome measure

Change in creatinine clearance after 24 hours of receiving, or not, furosemide infusion

Secondary outcome measures

Other outcome measures include rate of resumption of renal replacement therapy, peak creatinine, requirement for mineral replacement

Overall study start date

11/02/2002

Completion date

31/07/2007

Eligibility

Key inclusion criteria

50 patients. 1 per week.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

50

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

11/02/2002

Date of final enrolment

31/07/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Chelsea & Westminster Hospital

London United Kingdom SW10 9NH

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Chelsea and Westminster Healthcare NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration